These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 12079522

  • 1. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
    Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, Kanamori Y, Terakawa N.
    Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
    Komuro Y, Udagawa Y, Susumu N, Aoki D, Kubota T, Nozawa S.
    Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
    [Abstract] [Full Text] [Related]

  • 3. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
    Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Shimogai R, Kawaguchi W, Sato S, Terakawa N.
    Int J Gynecol Cancer; 2007 Nov; 17(1):76-82. PubMed ID: 17291235
    [Abstract] [Full Text] [Related]

  • 4. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
    Minagawa Y, Kigawa J, Irie T, Kanamori Y, Itamochi H, Cheng X, Terakawa N.
    Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
    [Abstract] [Full Text] [Related]

  • 5. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer.
    Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T, Terakawa N.
    Gynecol Oncol; 2002 Aug; 86(2):171-6. PubMed ID: 12144824
    [Abstract] [Full Text] [Related]

  • 6. Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines.
    Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K.
    Biol Pharm Bull; 2002 Jun; 25(6):771-8. PubMed ID: 12081145
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
    Itamochi H, Kigawa J, Akeshima R, Sato S, Kamazawa S, Takahashi M, Kanamori Y, Suzuki M, Ohwada M, Terakawa N.
    Oncology; 2002 Jun; 62(4):349-53. PubMed ID: 12138243
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
    Minagawa Y, Kigawa J, Itamochi H, Terakawa N.
    Hum Cell; 2001 Sep; 14(3):237-43. PubMed ID: 11774743
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.